.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018279

« Back to Dashboard
NDA 018279 describes K-TAB, which is a drug marketed by Abbvie and is included in one NDA. It is available from eighteen suppliers. Additional details are available on the K-TAB profile page.

The generic ingredient in K-TAB is potassium chloride. There are two hundred and twenty-five drug master file entries for this compound. Seventy-one suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the potassium chloride profile page.

Summary for NDA: 018279

Tradename:
K-TAB
Applicant:
Abbvie
Ingredient:
potassium chloride
Patents:0
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details

Pharmacology for NDA: 018279

Ingredient-typePotassium Compounds

Suppliers and Packaging for NDA: 018279

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
K-TAB
potassium chloride
TABLET, EXTENDED RELEASE;ORAL 018279 NDA AbbVie Inc. 0074-3023 0074-3023-13 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0074-3023-13)
K-TAB
potassium chloride
TABLET, EXTENDED RELEASE;ORAL 018279 NDA AbbVie Inc. 0074-3023 0074-3023-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0074-3023-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Approved Prior to Jan 1, 1982TE:BCRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength8MEQ
Approval Date:Aug 1, 1988TE:BCRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength20MEQ
Approval Date:Nov 25, 2013TE:BCRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc